USFDA Gives Final Approval to Cadila Healthcare to Market Mesalamine Tablets
Shital Jibhe / 07 Jun 2017
On Wednesday Cadila Healthcare announced that USFDA has given final approval to market Mesalamine Delayed-Released tablets USP, 1.2g in the US market.
On Wednesday Cadila Healthcare announced that USFDA has given final approval to market Mesalamine Delayed-Released tablets USP, 1.2g in the US market. Zydus Cadila was the first to file an ANDA (Abbreviated New Drug Application) for a generic version of Lialda (mesalamine).
The generic version of Lialda (mesalamine) will be produced at Moraiya Plant located at Ahmedabad. Lialda is used for the treatment of mild to moderate ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that affects approximately 700,000 people in the United States. The estimated brand sale for Mesalamine Delayed-Release
The group now has more than 115 approvals and has so far
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.